Concurrent trastuzumab - Internal mammary irradiation for HER2 positive breast cancer: "It hurts to be on the cutting edge"

Radiotherapy and Oncology

Volumn 94, Issue 1, 2010, Pages 119-120

  Belkacémi, Yazid ^a   Gligorov, Joseph ^b  

^a HENRI MONDOR HOSPITAL   (France)

^b HÔPITAL TENON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL; TRASTUZUMAB;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOTOXICITY; CARDIOVASCULAR RISK; COMPUTER ASSISTED TOMOGRAPHY; FOLLOW UP; HEART; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INTERNAL MAMMARY IRRADIATION; IRRADIATION; LETTER; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; SKIN TOXICITY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; GENES, ERBB-2; HUMANS; LYMPHATIC METASTASIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 74849130902     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2009.04.009     Document Type: Letter

References (11)

1. Shaffer R., Tyldesley S., Rolles M., et al. Acute cardiotoxicity with concurrent trastuzumab and radiotherapy including internal mammary chain nodes: a retrospective single-institution study. Radiother Oncol 90 (2009) 122-126
2. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 (2005) 1673-1684
3. Joensuu H., Kellokumpu-Lehtinen P.L., Bono P., et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354 (2006) 809-820
4. Smith I., Procter M., Gelber R.D., et al. 2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369 (2007) 29-36
5. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. N Engl J Med 353 (2005) 1659-1672
6. Belkacemi Y., Gligorov J., Ozsahin M., et al. Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: acute toxicity analyses from the French multicentric study. Ann Oncol 19 (2008) 1110-1116
7. Marks L.B., Hebert M.E., Bentel G., Spencer D.P., Sherouse G.W., and Prosnitz L.R. To treat or not to treat the internal mammary nodes: a possible compromise. Int J Radiat Oncol Biol Phys 29 (1994) 903-909
8. Borger J.H., Hooning M.J., Boersma L.J., et al. Cardiotoxic effects of tangential breast irradiation in early breast cancer patients: the role of irradiated heart volume. Int J Radiat Oncol Biol Phys 69 (2007) 1131-1138
9. Muehlbauer S, Revil C, Leyland-Jones B, et al. Pooled cardiac safety analysis of patients with HER2-positive metastatic breast cancer receiving trastuzumab (Herceptin®). In: 31st Annual San Antonio Breast Cancer Symposium, Dec 10-14, San Antonio; 2008. Abstract no. 6136.
10. Abu-Khalaf M.M., Juneja V., Chung G.G., et al. Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer. Breast Cancer Res Treat 104 (2007) 341-349
11. Harris E.R., Correa C., Huang W.-T., et al. J Clin Oncol 24 (2006) 4100-4106